Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription. Before the JAK inhibitors came out, we had ...

The incidence of serious adverse events did not differ significantly between combo therapy and monotherapy in patients with immune-mediated inflammatory diseases. However, specific combinations such ...

Patients with rheumatoid arthritis (RA) whose symptoms improved after they started taking nonbiologic disease-modifying antirheumatic drugs (DMARDs) also demonstrated restored balance in their oral ...

Worries have persisted that cancer survivors in remission might face increased recurrence risk when treated with biologic drugs for autoimmune disease. This Danish study of rheumatoid arthritis ...

Our objective was to describe characteristics and compare clinical and patient-reported outcomes (PROs) for disease-modifying antirheumatic drug (DMARD)-naive patients with psoriatic arthritis (PsA) ...

New research presented this week at ACR Convergence 2022, the American College of Rheumatology's annual meeting, showed that combining a nonsteroidal anti-inflammatory drug and TNF inhibitor did not ...

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...

Persistent and neuropathic pain occur frequently in rheumatoid arthritis, or RA, and tools that assess patient-reported outcomes can help clinicians determine the right care plan, according to the ...